Abstract
Abstract Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer, with high recurrence rate and short survival after metastasis. However, TNBC is a pathologically and clinically heterogenous disease. Chemotherapy is currently the main treatment choice for TNBC. Tremendous effort has been devoted to identifying new treatment regimen in high-risk or metastatic TNBC patients. Recent studies have classified TNBC into several distinct molecular subtypes and proposed new treatment regimen. In this presentation, the strategies to identify high-risk and decrease relapse in early TNBC patients will be discussed. Furthermore, new treatment strategies in specific subtypes of TNBC patients will be presented, including anti-androgen in androgen receptor-positive TNBC patients, PARP inhibitors in BRCA mutant or High HRD patients, combination immunotherapy, and other approaches. There has never been a better time for precise treatment in TNBC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
